pfizer glp-1 news China approves drug for weight management, ETPharma Pfizer Enters China GLP-1 Market

Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis

The spectrum ranges from simple steatosis (fat accumulation without significant inflammation) to nonalcoholic steatohepatitis (NASH), which involves inflammation and hepatocyte injury that can progress to fibrosis, cirrhosis, and hepatocellular carcinoma

Front Plant Sci 7:81

How Does It Stack Up

These check-ins happen at predictable intervals: typically at 2 weeks, 6 weeks, 12 weeks, and potentially beyond depending on your protocol length